Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 01 August 2016 | By Zachary Brennan
The European Medicines Agency (EMA) on Monday launched a public consultation on revised guidance for companies developing new drugs to treat tuberculosis (TB).
Comments on the guidance, which is an addendum to EMA’s guideline on the evaluation of medicines to treat bacterial infections, will be accepted until 31 January 2017.
TB, caused by a bacterium called Mycobacterium tuberculosis, affects 340,000 new people annually in the EU, and in 2014, 33,000 deaths were reported, mostly from eastern and central European countries.
In addition, multidrug-resistant tuberculosis (MDR-TB) poses a serious public health challenge and often affects migrant workers, refugees, displaced persons, prisoners or drug users.
EMA notes that existing TB treatments cannot effectively combat the disease because they are lengthy, complex, and generally show reduced efficacy against MDR-TB, meaning new TB medicines and regimens that are simpler to administer, of shorter duration and can overcome drug resistance are needed.
The revised guidance takes into account a developing trend in recent years, in which there has been a shift toward developing entirely new regimens to treat TB, rather than focusing on single medicines.
The update also clarifies the EU’s regulatory requirements for data that should be generated to support the approval of new medicines or combinations of medicines, and provides direction on evaluating the efficacy of individual new medicines and regimens in light of recently approved medicines; evaluating new regimens with at least one new medicine; and the role of biomarkers to predict the effectiveness of a new drug during clinical development.
“Since the adoption of the prior guidance advances have been made in the application of pharmacokinetic-pharmacodynamic (PK-PD) analyses to identify potentially efficacious doses and regimens for further clinical evaluation,” EMA says. “In particular, the use of in-vitro pharmacodynamic models early on in the development programme, with further refinement when human PK data become available, may play an important role in minimising the extent of dose- and/or regimen-finding clinical trials.”
Sections on microbiological data and patient selection also feature prominently in the new draft.
Comments on the revised guidance should be sent to idwpsecretariat@ema.europa.eu and EMA will host a workshop in November 2016 to discuss the comments.
EMA guidance
Tags: TB drugs, tuberculosis, drug development guidance EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.